# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Wilma Rudolph (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML036-SYN
- Date: 2026-07-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Gloria Haynes-Whitaker, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

MRI result and neuro-oncology consultation. **S**

## History of present illness

Ms. Rudolph returns three days after her first visit. The MRI the next morning showed a 3.8 cm ring-enhancing mass in the left posterior frontal lobe with central necrosis, surrounding edema and 5 mm of midline shift. Dr. Haynes-Whitaker telephoned her the same afternoon and started dexamethasone 4 mg twice a day with famotidine. Since then the morning headaches have eased and her words come more easily, though she still pauses now and then; the right hand is a little steadier. CT of the chest, abdomen and pelvis yesterday showed no cancer elsewhere. She has had no seizure, vomiting or drowsiness. She saw Dr. Brzezinski of neuro-oncology this morning, together with the neurosurgery team. She is not driving. She said that as a child she was told she would never walk, and that she wants the facts as they are. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| MRI | 3.8 cm ring-enhancing left posterior frontal mass with necrosis, edema and 5 mm midline shift; raised perfusion; no other lesion |
| CT body | No primary cancer elsewhere |
| Dexamethasone | 4 mg twice a day for two days; headache and speech better |
| Coordination | Neuro-oncology and neurosurgery seen today; awake craniotomy planned in six days |
| Her questions | What the mass is, whether surgery can take it out without harming her speech or hand, and what comes after |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, night sweats or weight loss |
| Neurological | Positive | Occasional word-finding pauses, improving; right hand slightly clumsy; headache much less; no seizure |
| Eyes | Negative | No double vision |
| Gastrointestinal | Negative | No nausea, vomiting or heartburn |
| Endocrine | Negative | No thirst or frequent urination |
| Psychiatric | Positive | Worried and sleeping poorly since the call; PHQ-9 7 and GAD-7 9; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day **S**
- Dexamethasone 4 mg oral tablet, one tablet twice a day with food, for symptomatic vasogenic edema, until surgery **S**
- Famotidine 20 mg oral tablet, one tablet twice a day while taking dexamethasone **S**

## Allergies

- No known allergy **S**

## Objective

BP 134/82 mmHg; pulse 78 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 67.8 kg; BMI 20.9 kg/m². All vital signs are synthetic.

Hemoglobin: 13 g/dL; White cell count: 11.8 10*3/uL (high); Platelets: 270 10*3/uL; Sodium: 140 mmol/L; Potassium: 4 mmol/L; Creatinine: 0.84 mg/dL; eGFR (CKD-EPI 2021): 83 mL/min/1.73 m²; Glucose: 138 mg/dL (high); INR: 1; aPTT: 29 s; Karnofsky Performance Status: 80; PHQ-9: 7; GAD-7: 9. All results are synthetic.

## Change since baseline

- Hemoglobin: 13.1 g/dL at baseline, 13 g/dL at this visit **S**
- White cell count: 7.1 10*3/uL at baseline, 11.8 10*3/uL (high) at this visit **S**
- Platelets: 262 10*3/uL at baseline, 270 10*3/uL at this visit **S**
- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4 mmol/L at this visit **S**
- Creatinine: 0.86 mg/dL at baseline, 0.84 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 80 mL/min/1.73 m² at baseline, 83 mL/min/1.73 m² at this visit **S**
- Glucose: 92 mg/dL at baseline, 138 mg/dL (high) at this visit **S**
- Karnofsky Performance Status: 80 at baseline, 80 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 67.8 kg; blood pressure 134/82, pulse 78 |
| Mental status and speech | Alert and oriented; fluent with rare word-finding pauses; naming 15 of 15; repetition and comprehension intact |
| Cranial nerves | Mild flattening of the right nasolabial fold; fundi without papilledema |
| Motor | Slight right pronator drift; right grip and finger extension 4+/5; legs 5/5 on both sides |
| Gait | Steady, normal stride; tandem gait slightly unsteady |
| Extremities | Left calf slightly smaller than the right, from childhood polio; no leg swelling |
| Psychiatric | Composed and direct; anxious when talking about her speech |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Left posterior frontal ring-enhancing mass, presumed high-grade glioma** (D49.6). A single ring-enhancing mass with necrosis and raised perfusion in a woman of 54 with no cancer elsewhere on CT is most likely a high-grade glioma; a solitary metastasis, lymphoma or abscess is much less likely on the imaging. Tissue is needed for the diagnosis, and removing as much tumor as is safe improves outcome. Dr. Brzezinski and the neurosurgery team recommend an awake craniotomy with language and motor mapping in six days, after functional MRI with tractography. Fit for surgery: blood count, chemistry and clotting normal. **S**
   - Functional MRI with tractography in four days.
   - Awake craniotomy with mapping in six days; the operating team will explain the awake part in advance.
   - Tissue for the integrated WHO CNS5 diagnosis, including IDH, TERT, EGFR, chromosome 7 and 10 and MGMT promoter methylation.
2. **Vasogenic cerebral edema with 5 mm midline shift** (G93.6). The edema, not the tumor alone, explains much of the headache and the speech and hand symptoms, and both are better on dexamethasone. Glucose 138 mg/dL (not fasting) and white cells 11.8 are the expected effects of the steroid. No antiseizure drug is needed because she has had no seizure. **S**
   - Continue dexamethasone 4 mg twice a day with famotidine until surgery, then taper.
   - Seizure first aid explained; call 911 for a seizure lasting more than five minutes.
3. **New headache, word-finding pauses and right-hand clumsiness** (R29.818). Explained by the mass and edema found on MRI; superseded. **S**
   - Problem resolved.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | MRI of the brain with and without contrast | At once for new progressive focal symptoms | Up to date | The morning after the first visit: ring-enhancing left frontal mass with necrosis, edema and midline shift |
| Imaging | Advanced MRI sequences (diffusion and perfusion) | With the diagnostic MRI | Up to date | No restricted diffusion in the necrotic center (abscess unlikely); raised relative cerebral blood volume in the rim (high-grade tumor likely) |
| Imaging | CT of the chest, abdomen and pelvis | When a metastasis is possible | Up to date | Yesterday: no primary cancer elsewhere |
| Imaging | Functional MRI with tractography | Before surgery near language or motor areas | Ordered | In four days |
| Examination | Neurologic examination (language, strength, gait) | Each visit | Completed today | Rare word-finding pauses; slight right pronator drift; right grip 4+/5; better than at the first visit |
| Survey | Performance status (Karnofsky) | Each visit | Completed today | Karnofsky 80 |
| Medication safety | Dexamethasone: indication, dose and effects | When started and at each visit | Completed today | Started for edema causing symptoms at 4 mg twice a day; glucose 138 mg/dL and white cells 11.8 on the steroid; famotidine for stomach protection; taper after surgery |
| Laboratory | Preoperative blood count, chemistry and clotting | Within 30 days before surgery | Completed today | Hemoglobin 13.0 g/dL, platelets 270; sodium 140, potassium 4.0, creatinine 0.84 mg/dL, eGFR 83; INR 1.0, aPTT 29 seconds |
| Medication safety | Seizure history and antiseizure drug need | At diagnosis and each visit | Not indicated | No seizure has occurred, so no prophylactic antiseizure drug, as the SNO-EANO guideline advises |
| Examination | Signs of leg clot or pulmonary embolism | Each visit; brain tumors carry a high thrombosis risk | Completed today | No leg swelling or breathlessness; hospital prophylaxis after surgery planned |
| Referral | Neuro-oncology and neurosurgery | Within a week of an MRI showing a probable brain tumor | Completed today | Seen this morning; recommendations in the consultation note |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, each treatment phase, and when symptoms change | Completed today | PHQ-9 7 and GAD-7 9, mild, with worry about the diagnosis; no thoughts of self-harm |
| Self-management | Driving | From the first focal symptom | Completed today | Not driving; reviewed again after surgery and treatment |
| Self-management | Falls, leg strength and late effects of polio | Each visit | Completed today | No falls; legs strong; uses the handrail on stairs while the right hand is weak |

## Goal progress

- MRI of the brain within 24 hours and a neuro-oncology and neurosurgery plan within one week of presentation. Outcome by 2026-07-02: MRI the next morning; consultation three days after the first visit. **S**
- Maximal safe resection within two weeks of the MRI, preserving language and right-hand strength. In progress; target 2026-07-29. **S**
- Radiotherapy with daily temozolomide started within six weeks of surgery and completed on schedule. In progress; target 2026-09-14. **S**
- Dexamethasone tapered off within five weeks of surgery, with glucose back to normal. In progress; target 2026-09-14. **S**
- No falls, and walking independently, through treatment. In progress; target 2026-10-09. **S**
- Palliative care involved and her wishes recorded before adjuvant treatment begins. In progress; target 2026-10-09. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers (2026), National Comprehensive Cancer Network
- Weller M, et al. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 2021;18(3):170-186 (PMID 33293629) (2021), European Association of Neuro-Oncology
- Louis DN, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23(8):1231-1251 (PMID 34185076) (2021), Neuro-Oncology (WHO Classification of Tumours)
- Walbert T, et al. SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Neuro Oncol 2021;23(11):1835-1844 (PMID 34174071) (2021), Society for Neuro-Oncology and European Association of Neuro-Oncology
- Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023), American Society of Clinical Oncology
- Farbu E, et al. EFNS guideline on diagnosis and management of post-polio syndrome. Eur J Neurol 2006;13(8):795-801 (PMID 16879288) (2006), European Federation of Neurological Societies
- CMID: Clinical Monitoring Intelligence Database, depression monograph (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Functional MRI in four days and surgery in six. Primary care review about three weeks after surgery with the pathology. Go to the emergency department for a seizure, worsening speech or weakness, vomiting or drowsiness. **S**
- Next scheduled visit 2026-07-29: review three weeks after awake craniotomy: pathology and molecular diagnosis, steroid taper, steroid-related hyperglycemia, falls, and the plan for radiotherapy with temozolomide. **S**
